After the historic approval of the company’s first-ever drug in January 2021, Aurinia Pharmaceuticals announced the acquisition of two pipeline assets that align with the Canadian biotech’s focus on autoimmune and kidney-related disease.
https://www.pharmalive.com/wp-content/uploads/2021/08/Eight-Months-After-First-FDA-Approval-Aurinia-Picks-Up-Two-More-Candidates-BioSpace-8-17-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-08-17 11:38:322021-08-17 14:07:52Aurinia Picks Up Two Pipeline Assets